Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sorafenib + tislelizumab
- Development stage
- Phase 2
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of sorafenib, a multi-kinase inhibitor, and tislelizumab, an anti-PD-1 monoclonal antibody. This combination is being investigated for the treatment of unresectable hepatocellular carcinoma (HCC). Sorafenib targets multiple kinases involved in tumor growth and angiogenesis, while tislelizumab blocks the interaction between PD-1 and its ligands, enhancing T-cell immune responses against cancer cells. The combination demonstrates promising antitumor activity in the first-line treatment of HCC, with a relatively high objective response rate and acceptable safety profile.
- Brand names
- TeventriBaizeanNexavar
- Other names
- tilelizumabtislelizumabsorafenib
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR4 (Vascular endothelial growth factor Receptor-3)VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)PDGFRB (Platelet-derived growth factor receptor beta)RAF1 (c-Raf-1 (Y340D/Y341D))
Beyond the preview
Go deeper on sorafenib + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sorafenib + tislelizumab.